Rodríguez MH

Language: Spanish
References: 34
Page: 78-90
PDF size: 119.93 Kb.

ABSTRACT

Blood transfusion cero risks associated infections has not been attended. Bacteria, virus and parasites can be transfusion-transmitted. Preventive measures must be taken are: donor´s clinical history and serological test in its blood samples. After this measures there is a residual risk:
• For bacteria contamination (out of Treponema pallidum) one in 15 to 30 thousand transfusions concentrated platelets, and 0.21 per million erythrocyte concentrates transfusions.
• Virus transfusions, hepatitis B: one in 500,000 transfusions; hepatitis C one in 1-2 million and same, also, for human immunodeficiency virus. For hepatitis B there is a risk of contamination by occult infections in donors, because virus permanence in hepatic cells, not detectable by serologic tests. Human immunodeficiency virus in Mexico has a residual risk very semblable to developed countries finds. Chagas disease, serological reactivity has a 0.406% prevalence in Mexico. There have been blood transfusion patients contamination, seven in USA and Canada and four in Mexico reported, all of them asymptomatic. Emerging infections as Nilo West or dengue virus are not reported as blood transfusions contamination in Mexico. Probably, the relative low risk of transfusion transmitted infections in Mexico is related with its clime, geographic situation and possible genetic factors.

REFERENCES

1. Perkins HA, Busch MP. Transfusion associated infection: 50 years of relentless challenges and remarkable progress. Transfusion 2010; 50: 2080-2099.

2. Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008; 1112: 2617-2626.

3. Guía Para el Uso Clínico de la Sangre. Secretaría de Salud, Asociación Mexicana de Medicina Transfusional, A.C., Agrupación Mexicana para el Estudio de la Hematología, A.C. Tercera edición, Enero 2007. México.

4. Dwyre DM, Fernando LP, Et Holland P. Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st Century. Vox Sanguinis 2011; 100: 92-98.

5. Stites DP, Stobo JD, Fudemberg HH, Wells JV. Basic & clinical immunology. 4th Edition. Lange Medical Publications 1982. p. 227.

6. Murphy K, Travers P, Walport M. Janeway´s immunobiology. Seventh edition. Garland Science. New York and London. 2008.

7. Scheiblauer H, El-Nageli M, Díaz S, Nick S, Zeichhardt H, Gruner HP, Et Prince A. Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with and array of genotypes and HBs subtypes. Vox Sanguinis 2010; 98: 403-414.

8. Coffin PO, Stevens AM, Scott JD, Stekler JD, Galden MR. Patients acceptance of universal screening for hepatitis C virus infection. BMC Infectious Diseases 2011; 11: 160-165.

9. Polesky H, Hanson M. Hepatitis B-Serologic markers. In: Hepatitis a technical workshop. Ed Creating L, Silvergleid AJ. American Association of Blood Banks. Chicago, Illinois, 1981: pp. 15-32.

10. Hollinger EB. Hepatitis B virus infection and transfusion medicine science and the occult. Transfusion 2008; 48: 1001-1026.

11. Alter HJ. Post-transfusion hepatitis: Prologue progress and prospects. In: Hepatitis B-Serologic markers. In: Hepatitis, a technical workshop. Ed Creating L, Silvergleid AJ. American Association of Blood Banks. Chicago, Illinois, 1981: pp. 47-66.

12. Stramer S. Performance of and algorithm for the reentry of volunteer blood donors deferred due to false-positive test results for antibody to hepatitis B core antigen. Transfusion 2008; 48: 2315-2322.

13. Allain JP. Occult hepatitis B virus infection: Implications in transfusion. Vox Sanguinis 2004; 86: 83-91.

14. Allain JP. International collaborative study proposal for the characterization of occult hepatitis B virus infection identified by nucleic acid or anti-HBc screening. Vox Sang. 2007; 92: 254-257.

15. Dawson GJ. HCV core antigen and combination (antigen/antibody) assays for the detection of early seroconversion. J Med Virology 2007; 79: S54-S58.

16. Sánchez-Guerrero A. Sangre segura en México logros y Retos. Rev Invest Clin 2011; 63: 306-310.

17. Orozco-Santana A, Montes de Oca-Acosta E, Rivera-López R, Ambriz-Fernández R et al. Estudio comparativo de serología reactiva con prueba de quimioluminiscencia y ácidos nucleicos (NAT) en donadores del Banco Central de Sangre del Centro Médico Nacional Siglo XXI del primero de enero al 31 de diciembre de 2009. Rev Mex Med Tran 2010; 3 Supl. 1: S105.

18. Informe Nacional Sobre los Progresos en Relación con la Aplicación del UNGASS/SIDA, México 2010.

19. Malagón-Martínez A, Guerra-Márquez A, Pichardo-Martínez MT, Gómez-Corona J. Rendimiento del escrutinio de la prueba de ácidos nucleicos (NAT) en donadores de sangre en la seguridad transfusional. Rev Mex Med Tran 2010; 3: S118.

20. Duque-Rodríguez J, Avitia-Estrada A, González-Duque ML, Ochoa-Portillo BE et al. Utilidad de las pruebas de ácidos nucleicos (P de NAT) en bancos de sangre. Experiencia del Centro Estatal de Transfusión Sanguínea, Chihuahua. Rev Mex Med Tran 2010; 3: S104.

21. Devare SG. Early diagnosis of HIV infection. J Med Virol 2007; 79: S11-S15.

22. Baptista-González HA. Lo que no sabemos y lo que debemos saber acerca de las pruebas moleculares en el tamiz de infecciones transmitidas por infección en donadores de sangre en México. Rev Mex Med Tran 2009; 2: 30-40.

23. Wendell S, Brener Z. Historical aspects. In: Chagas Disease (American Trypanosomiasis): its impact on transfusion and clinical medicine. In: Wendell S, Brener Z, Camargo ME, Rassi A. ISBT, Brazil´92. Sao Paulo, Brazil pp. 5-12.

24. Chiari Egler. Diagnostic test for Chagas disease. In: Wendell S, Brener Z, Camargo ME, Rassi A. ISBT, Brazil´92. Sao Paulo, Brazil pp. 153-164.

25. Kirchoff LV, Paredes P, Lomelí-Guerrero A, Paredes-Espinosa M, Ron-Guerrero CS, Delgado-Mejía M, Peña-Muñoz JG. Transfusion-associated Chagas disease (American Trypanosomiasis) in Mexico: Implications for transfusion medicine in the United States. Transfusion 2006; 46: 298-304.

26. Wendell S, Pinto-Diaz JC. Transfusion transmitted Chagas disease. In: Chagas Disease (American Trypanosomiasis): its impact on transfusion and clinical medicine. In: Wendell S, Brener Z, Camargo ME, Rassi A. ISBT, Brazil´92. Sao Paulo, Brazil pp. 103-133.

27. Sousa HM. The present state of chemoprophylaxis in transfusional Chagas disease (editorial) Rev Soc Bras Med Trop 1982; 22: 1-3. In: Wendell S, Brener Z, Camargo ME, Rassi A. ISBT, Brazil´92. Sao Paulo, Brazil pp. 103-133.

28. Gudino MD, Linares J. Chagas disease and blood transfusion. In: Westphal RG, Carson KB, Turc JM eds. Emerging Global Paterns in Transfusion Transmitted Infections. Arlinton VA: American Association of Blood Banks 1990, pp. 65-86.

29. Novelo-Garza BA, Benítez-Arvizu A, Peña-Benítez J, Galván-Cervantes J, Morales-Rojas A. Detección de Trypanosoma cruzi en donadores de sangre. Rev Med Inst Mex Seguro Soc 2010; 48: 139-144.

30. Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR and Dodd RY. Emerging infections disease agents and their potential thread to transfusion safety. Transfusion 2009; 49 August Suppl: 1S-29S.

31. Sánchez-Guerrero SA, Romero-Estrella S, Rodríguez-Ruiz A, Gómez A et al. Detection of West Nile virus in the Mexican blood supply. Transfusion 2006; 46: 111-117.

32. Malagón-Martínez A, Magaña-Duarte R, Novelo-Garza B, Guerra-Márquez A et al. Prevalencia de la infección del virus del Oeste del Nilo en candidatos a donación de sangre. Rev Mex Med Tran 2010; 3: S105.

33. Teo D, Ng LC, Lam S. Is dengue a threat to blood supply? Transfusion Medicine 2009; 19: 66-77.

34. Rodríguez-Rodríguez D, Garza-Rodríguez M, Chavarría AM, Ramos-Jiménez J et al. Dengue virus antibodies in blood donors from and endemic area. Transfusion Medicine 2009; 19: 125-131.